Glivec (that is imatinib mesylate) is a tyrosine kinase inhibitor previously approved by the FDA for treating CML and for treating patients with Kit (CD117) positive metastatic and/or unresectable malignant gastrointestinal stromal tumors (GIST). This evidence concerns the gene KIT and gastrointestinal stromal tumor.